Abstract:

Objective  To observe the effects of camrelizumab monoclonal antibody combined with chemo⁃therapy on the expressions of cytokeratin 19 fragment antigen 21⁃1（CY211），matrix metalloproteinase⁃9（MMP⁃9）and tumor growth and metastasis in elderly patients with non⁃small cell lung cancer（NSCLC）. Methods  FromJanuary 2017 to October 2019，120 elderly NSCLC patients were randomly divided into observation group andcontrol group，with 60 cases in each group. The control group was treated with chemotherapy，while the observationgroup was treated with camrelizumab monoclonal antibody combined with chemotherapy. The therapeutic effect wasevaluated after 3 cycles，and the changes of serum CY211，MMP⁃9 expressions and tumor growth and metastasiswere compared before and after treatment. Results  After treatment，the total effective rate of the observationgroup was significantly higher than that of the control group（P < 0.05）. The levels of serum CY211，MMP⁃9 andvascular endothelial growth factor（VEGF）in the two groups were lower than those before treatment，and the obser⁃vation group was lower than the control group（P < 0.05）. The Karnofsky Performance Scale（KPS）score of bothgroups was higher than that before treatment，and the observation group was higher than the control group（P <0.05）. Conclusions Camrelizumab monoclonal antibody combined with chemotherapy has a significant effect onelderly NSCLC patients，which can significantly reduce the levels of serum CY211，MMP⁃9 and VEGF，reduceneovascularization，inhibit tumor growth and metastasis，and improve the quality of life of the patients.

Key words: camrelizumab monoclonal antibody, chemotherapy, non?small cell lung cancer, cyto?keratin 19 fragment antigen 21?1, matrix metalloproteinase?9, growth and metastasis